Literature DB >> 16710679

[Metastases with CUP syndrome].

S Seeber1, D Strumberg.   

Abstract

Carcinoma of unknown primary is common, accounting for 2-6% of all cancer patients. The primary site is found in less than 25% of patients before death and frequently goes undiscovered at postmortem examination. At the time point of first diagnosis of CUP syndrome, usually more than 80% of the patients present a disseminated situation. Prognosis depends on the involved site and is unaffected by whether or not the primary site is ever found. For patients presenting with metastasis to peripheral lymph nodes, node dissection may be curative. In patients with small cell malignancies, peritoneal carcinomatosis (in women), poorly differentiated carcinomas involving external lymph nodes, mediastinum, or retroperitoneum, but without metastases to viscera or bone, objective long-term responses are possible with combination chemotherapy. For all other patients, toxic therapies are recommended only for patients with good functional status, for palliation of symptoms when they develop, and for continuous support of the quality of life.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16710679     DOI: 10.1007/s00120-006-1054-2

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  40 in total

1.  Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases.

Authors:  G Vlastos; M E Jean; A N Mirza; N Q Mirza; H M Kuerer; F C Ames; K K Hunt; M I Ross; T A Buchholz; A U Buzdar; S E Singletary
Journal:  Ann Surg Oncol       Date:  2001-06       Impact factor: 5.344

Review 2.  Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients.

Authors:  T Le Chevalier; E Cvitkovic; P Caille; J Harvey; G Contesso; M Spielmann; J Rouesse
Journal:  Arch Intern Med       Date:  1988-09

3.  PET with 2-[F-18]-fluoro-2-deoxy-D-glucose (FDG) in patients with cancer of unknown primary (CUP): influence on patients' diagnostic and therapeutic management.

Authors:  Panagiota Mantaka; Richard P Baum; Andreas Hertel; Stefan Adams; Andreas Niessen; Sonali Sengupta; Gustav Hör
Journal:  Cancer Biother Radiopharm       Date:  2003-02       Impact factor: 3.099

Review 4.  Prognostic stratification in UPC: a role for assessing the value of conventional-dose and high-dose chemotherapy for unknown primary carcinoma.

Authors:  Everardo D Saad; James L Abbruzzese
Journal:  Crit Rev Oncol Hematol       Date:  2002-02       Impact factor: 6.312

5.  Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site.

Authors:  A van der Gaast; J Verweij; A S Planting; W C Hop; G Stoter
Journal:  J Clin Oncol       Date:  1995-07       Impact factor: 44.544

6.  Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience.

Authors:  J D Hainsworth; D H Johnson; F A Greco
Journal:  J Clin Oncol       Date:  1992-06       Impact factor: 44.544

7.  An analysis of 1539 patients with cancer of unknown primary site.

Authors:  E Altman; E Cadman
Journal:  Cancer       Date:  1986-01-01       Impact factor: 6.860

8.  [Immunohistochemical diagnosis in cancer metastasis of unknown primary tumor].

Authors:  O Kaufmann; E Fietze; M Dietel
Journal:  Pathologe       Date:  2002-05       Impact factor: 1.011

9.  Occult breast cancer presenting with axillary metastases. Updated management.

Authors:  P L Baron; M P Moore; D W Kinne; F C Candela; M P Osborne; J A Petrek
Journal:  Arch Surg       Date:  1990-02

10.  Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin.

Authors:  J L Abbruzzese; M C Abbruzzese; R Lenzi; K R Hess; M N Raber
Journal:  J Clin Oncol       Date:  1995-08       Impact factor: 44.544

View more
  2 in total

Review 1.  Cutaneous metastases of visceral tumours: a review.

Authors:  Dorothée Nashan; Marcel Lucas Müller; Markus Braun-Falco; Sebastian Reichenberger; Rolf-Markus Szeimies; Leena Bruckner-Tuderman
Journal:  J Cancer Res Clin Oncol       Date:  2008-06-17       Impact factor: 4.553

2.  [Carcinoma of unknown primary site (CUP syndrome)].

Authors:  A Sendler; D Strumberg; A Tannapfel
Journal:  Chirurg       Date:  2008-07       Impact factor: 0.955

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.